Inactive Instrument

Almirall SA Share Price CBOE EUROPE EQUITIES

Equities

ES0157097017

Pharmaceuticals

End-of-day quote CBOE EUROPE EQUITIES
- EUR - Intraday chart for Almirall SA

Financials

Sales 2024 * 971M 1.05B 87.23B Sales 2025 * 1.07B 1.15B 96.13B Capitalization 1.82B 1.96B 163B
Net income 2024 * 25M 26.9M 2.24B Net income 2025 * 62M 66.72M 5.57B EV / Sales 2024 * 1.79 x
Net cash position 2024 * 81.01M 87.17M 7.27B Net cash position 2025 * 115M 123M 10.29B EV / Sales 2025 * 1.59 x
P/E ratio 2024 *
84.4 x
P/E ratio 2025 *
30.3 x
Employees -
Yield 2024 *
2.15%
Yield 2025 *
2.18%
Free-Float 34.78%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer - 25/14/25
Director of Finance/CFO 54 11/19/11
Chief Tech/Sci/R&D Officer - 07/21/07
Members of the board TitleAgeSince
Director/Board Member 81 29/07/29
Director/Board Member - 01/16/01
Director/Board Member 65 01/20/01
More insiders
Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.
More about the company